To compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary).
b For participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving. c Paclitaxel < 700 mg; Oxaliplatin < 800 mg; Docetaxel < 300 mg; Cisplatin < 300 mg.
d Paclitaxel 700-1400 mg; Oxaliplatin 800-1000 mg; Docetaxel 300-600 mg; Cisplatin 300-600 mg.
e Paclitaxel > 1400 mg; Oxaliplatin > 1000 mg; Docetaxel > 600 mg; Cisplatin > 600 mg.
f Neurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems. 
